This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication. Coverage details are drawn from official CMS and Medicare.gov materials; verify your specific situation with your plan.
For years, Medicare's rules blocked coverage of GLP-1 weight loss medications like Wegovy and Zepbound for the one condition they were designed to treat: obesity. Diabetes coverage was fine. Heart disease coverage was fine. But if you were an older adult with a BMI of 34 and creaky joints, $1,349 a month out of pocket was the wall you hit.
That wall came down on July 1, 2026. The Medicare GLP-1 Bridge program is a two-and-a-half-year pilot that puts three brand-name GLP-1s within reach of most Medicare beneficiaries at a flat $50 per month. This guide walks you through exactly who qualifies, what's covered, how to get your prescription filled, and where to turn if the Bridge doesn't fit your situation.
---
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a coverage pilot administered by CMS that runs from July 1, 2026 through December 31, 2027. It exists because Congress and CMS wanted a pathway for older adults with obesity to access GLP-1 medications while a longer-term policy framework is developed.
Three things make this program different from ordinary Part D coverage:
- Flat $50 monthly cost. Every eligible beneficiary pays the same $50, regardless of income, plan type, or which of the three covered drugs they receive.
- $50 does not count toward your deductible or out-of-pocket cap. The Bridge sits outside your Part D benefit structure. Nothing you pay through the Bridge shortens the path to the catastrophic coverage phase for your other medications.
- Not eligible for the Medicare Prescription Payment Plan (MPPP). You cannot spread the $50 across the year using MPPP smoothing.
The takeaway: the Bridge is a standalone, temporary access program. Treat it as a separate benefit sitting alongside your regular Part D coverage, not a modification of it.
---
Which GLP-1 Drugs Does the Bridge Cover?
Only three medications qualify. This list is exact and short — not every form of every drug is included.
| Drug | Form(s) Covered | Manufacturer |
|---|---|---|
| Wegovy | Weekly injection and the new oral tablet (FDA approved July 30, 2026) | Novo Nordisk |
| Zepbound | KwikPen only — single-dose pens and vials are not covered | Eli Lilly |
| Foundayo (orforglipron) | Oral tablet (once daily, no food restrictions) | Eli Lilly |
What's NOT covered under the Bridge: Ozempic, Mounjaro, Trulicity, Saxenda, Victoza, compounded semaglutide or tirzepatide, and — importantly — the Zepbound single-dose pen and Zepbound vials. If your current prescription is for Zepbound single-dose pens, ask your prescriber whether the KwikPen is an appropriate switch.
The Wegovy oral tablet is worth calling out. It was FDA approved on July 30, 2026 and is expected to reach retail pharmacies through the fall. If needles are a dealbreaker for you, the pill form of Wegovy is now Bridge-eligible from day one.
---
Am I Eligible? The 4-Point Checklist
To qualify for the Bridge program, you must meet all four of these requirements. If any one fails, you're out — but keep reading, because several failure modes still lead to coverage through other pathways.
Eligibility Checklist
☐ 1. You have Medicare Part D drug coverage.
This can be a standalone Part D drug plan or a Medicare Advantage plan that includes drug coverage (called MAPD). You are NOT eligible if your only Medicare coverage is through a private fee-for-service plan, a cost contract plan, or a PACE organization. If you're not sure what type of plan you have, call 1-800-MEDICARE (1-800-633-4227) or check your plan card.
☐ 2. You are NOT already receiving a GLP-1 through your Medicare drug plan.
If your plan already pays for Ozempic, Mounjaro, Trulicity, semaglutide, tirzepatide, orforglipron, dulaglutide, or liraglutide for any reason, you have to keep getting it through your plan. You cannot switch into the Bridge to lower your copay. This rule exists to keep the pilot targeted at patients who otherwise wouldn't have access.
☐ 3. You do NOT have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease.
If you have any of these, contact your Part D plan directly. Wegovy for cardiovascular risk reduction, Ozempic for diabetes, and Zepbound for sleep apnea are all separately eligible for standard Part D coverage — often at similar or better costs than the Bridge.
☐ 4. You are 18 or older AND meet one of three BMI thresholds:
- BMI of 35 or higher — no additional condition required.
- BMI of 30 or higher AND one of: certain types of heart failure, high blood pressure that's hard to control, or chronic kidney disease (stage 3a or above).
- BMI of 27 or higher AND one of: prediabetes, or a history of heart attack, stroke, or blocked arteries in your legs or arms (peripheral artery disease).
BMI is calculated from your height and weight. If you don't know yours, ask your doctor's office — it's on nearly every recent chart.
Pass all four? You qualify. Move to the enrollment steps below.
---
What If You Don't Qualify: Your Backup Coverage Paths
If one of the four requirements knocked you out, one of these pathways may still work for you:
- You have type 2 diabetes: Ozempic, Mounjaro, and Trulicity are standard Part D-covered medications for diabetes. Copays vary by plan — call your plan for exact numbers.
- You have moderate-to-severe obstructive sleep apnea: Zepbound is now FDA-labeled for OSA and covered under many Part D plans for this indication.
- You've had a heart attack, stroke, or have established cardiovascular disease: Wegovy has a CV risk-reduction label and is covered under Part D for that use in many plans.
- You have fatty liver disease (MASH): Rezdiffra is Part D-eligible; some plans now cover semaglutide off-label for MASH.
- You're on a private fee-for-service, cost contract, or PACE plan: Consider switching to a standard Part D or MAPD plan during Medicare Open Enrollment (October 15 - December 7 each year).
- You don't meet BMI thresholds: The manufacturer savings programs (LillyDirect, NovoCare) may still lower your cost significantly if you're commercially insured through a working spouse or a retiree health plan.
---
How to Enroll: The 6 Steps to Your First $50 Refill
There is no application form to fill out. Enrollment happens through your prescriber and pharmacy. Here's the exact sequence.
Step-by-Step Enrollment
Step 1: Book a visit with your primary care provider or a qualified GLP-1 prescriber. Bring your Medicare card, a recent height and weight measurement (or ask them to take one), and a full list of your current medications. Tell the office in advance that you want to discuss the Medicare GLP-1 Bridge program specifically — this saves a lot of appointment time.
Step 2: Confirm your eligibility with the prescriber. Your doctor will review the four criteria and confirm your BMI plus qualifying condition (if applicable). This is also when you'll discuss which of the three covered drugs is right for you.
Step 3: Prescription sent to pharmacy. Your prescriber sends the electronic prescription to the pharmacy of your choice — a standard retail pharmacy (CVS, Walgreens, Walmart, grocery-store pharmacy) or a mail-order pharmacy affiliated with your Part D plan.
Step 4: Pharmacy verifies your Medicare ID. The pharmacy will ask for the Medicare ID number printed on your red-white-and-blue Medicare card. If you don't have your card handy, they can look up your number using the last four digits of your Social Security Number. This is normal — don't be surprised.
Step 5: Your doctor submits the coverage form. Once the pharmacy confirms Bridge eligibility on their end, your doctor submits a short approval form to Medicare. You don't fill anything out. This happens behind the scenes and usually completes within a few business days.
Step 6: Watch for your Medicare confirmation letter, then pick up your first refill. Medicare will mail you a letter confirming coverage. When you pick up your medicine at the pharmacy, you'll pay $50 for a one-month supply. Every future refill of the same drug is $50 — even if your dose changes — without needing a new Medicare approval.
Important: If you switch drugs during the program (for example, from Zepbound KwikPen to Wegovy), your doctor will need to submit a new coverage form for the new medication.
---
Working with Your Local Insurance Portal
Most Medicare beneficiaries have a plan-specific online portal — MyHumana, Aetna Medicare Member Portal, UnitedHealthcare Medicare, WellCare, Kaiser, Blue Cross Blue Shield Medicare, and others. Even though Bridge enrollment doesn't require you to fill out a form, these portals are still useful for:
- Confirming you have Part D drug coverage. Log in and find the "Coverage Summary" or "Plan Details" page. It will show whether prescription drug coverage is included.
- Reviewing your plan's GLP-1 coverage. Use the drug lookup or formulary search tool. Search for "Wegovy," "Zepbound," and "Ozempic." If your plan already lists them as covered for any of your medical conditions, you may not need the Bridge at all.
- Downloading your Medicare ID. If you've lost your physical card, most portals offer a digital ID card download.
- Tracking your Bridge approval status. After your doctor submits the form, some plans will show a "Prior Authorization" or "Special Coverage" entry in your account within 3-7 business days.
If you don't have an online portal account set up, call the member services number on the back of your plan card. A representative can walk you through eligibility and coverage in real time. Have your Medicare ID, plan ID, and date of birth ready before you call — this speeds things up dramatically.
The single most useful call you can make before your doctor's appointment: call your plan's member services and ask, "Does my plan cover Wegovy, Zepbound, or Foundayo for weight loss? And am I eligible for the Medicare GLP-1 Bridge program?" That one question gets you the exact answer for your situation.
---
What If You're Not Eligible — or Want a Faster Path?
The Bridge program is a real advance for older Americans with obesity, but it has limits. It doesn't cover everyone. It requires an in-person or established telehealth relationship with a prescriber who's familiar with the paperwork. And the initial approval, while not lengthy, isn't same-day.
If you don't qualify for the Bridge, or you want a simpler telehealth workflow that handles the entire prescription and coverage question in one visit, two options are worth knowing:
- Ro.co GLP-1 Program: Ro's weight loss program includes an online medical assessment, a licensed prescriber, insurance verification (they check whether your commercial or Medicare plan covers Wegovy, Zepbound, or Foundayo), and access to compounded GLP-1 alternatives when medically appropriate. Best for people who want the entire process in one online workflow.
- SkinnyRx: Telehealth-first GLP-1 program that specializes in fast prescriber consults, insurance-savings-card enrollment for Wegovy and Zepbound, and Foundayo access via LillyDirect integration. Best for people who already know which drug they want and just need a prescriber.
Both platforms can determine within a single visit whether the Medicare Bridge is the best path for you or whether a commercial savings program, manufacturer copay card, or telehealth cash-pay option is cheaper or faster.
For a broader breakdown of every GLP-1 cost pathway in 2026 — commercial insurance, manufacturer savings, telehealth, LillyDirect, and NovoCare direct pricing — see our 2026 GLP-1 cost guide.
---
Common Questions About the Medicare GLP-1 Bridge
Does the $50 apply if I need a higher dose?
Yes. Dose changes do not require a new Medicare approval. Your $50 monthly cost stays the same at every dose level.
Can I use the Bridge and my Part D plan for other medications simultaneously?
Yes. The Bridge is separate from your Part D benefit. Your other prescriptions continue to run through your Part D plan normally.
Does the Bridge cover compounded GLP-1s?
No. Only the three named brand-name products — Wegovy, Zepbound KwikPen, and Foundayo — are covered.
What happens after December 31, 2027?
The pilot ends. CMS is expected to announce follow-on policy before that date. If the pilot is not extended or replaced, Bridge coverage stops and beneficiaries would need to transition to whatever standard Part D coverage exists at that time.
My spouse has commercial insurance. Can I use their coverage instead?
If you're primary-covered under Medicare, generally no — but manufacturer savings cards (Novo Care, LillyDirect) sometimes have provisions for beneficiaries with dual coverage. Talk to a telehealth intake specialist or a Medicare SHIP counselor (State Health Insurance Assistance Program — free) for your specific situation.
Where do I get free, unbiased help understanding my options?
The SHIP program offers free Medicare counseling by trained volunteers in every state. Call 1-877-839-2675 or use the online locator to find your state's office. This is the single best free resource for older adults navigating Medicare drug coverage.
---
Bottom Line
The Medicare GLP-1 Bridge is the first meaningful weight loss medication pathway Medicare has ever offered. If you're 65+, on Part D, meet the BMI and health-condition criteria, and haven't already been getting a GLP-1 through your plan, $50 a month for Wegovy, Zepbound KwikPen, or Foundayo is a genuine breakthrough in access.
The steps are simple: check your Part D coverage, confirm your BMI plus one qualifying condition, book a prescriber visit, and let your doctor and pharmacy handle the paperwork. Within 1–2 weeks of your first appointment, you should be walking out of the pharmacy with a covered prescription.
If you're ready to move now, a telehealth visit is the fastest way to get an evaluation, prescription, and insurance verification in one workflow:
Check GLP-1 eligibility with Ro.co → Talk to a SkinnyRx prescriber →
GLPTree has affiliate relationships with Ro.co and SkinnyRx. We earn a commission when you sign up through our links, at no additional cost to you. This does not affect coverage eligibility or your $50 Medicare Bridge cost. See our affiliate disclosure.
---
Frequently Asked Questions
What is the Medicare GLP-1 Bridge program?
A pilot coverage program that started July 1, 2026 and runs through December 31, 2027, allowing eligible Medicare Part D members to pay $50/month for Wegovy (injection or tablet), Zepbound KwikPen, or Foundayo (orforglipron). The $50 applies at every income level and does not count toward your Part D deductible.
Who is eligible for the Medicare GLP-1 Bridge program?
You must have Medicare Part D, not currently receive a GLP-1 through your plan, not have type 2 diabetes/moderate-to-severe sleep apnea/fatty liver disease (those already qualify for standard coverage), and meet one BMI threshold: BMI 35+, or BMI 30+ with heart failure/hard-to-control HBP/CKD 3a+, or BMI 27+ with prediabetes or history of heart attack/stroke/PAD.
Which GLP-1 drugs are covered under Medicare GLP-1 Bridge?
Three drugs: Wegovy (injection or new oral tablet), Zepbound KwikPen only, and Foundayo (orforglipron tablet). Zepbound single-dose pens and vials are NOT covered. Ozempic, Mounjaro, Trulicity, Saxenda, and Victoza are not part of the Bridge.
How do I enroll in the Medicare GLP-1 Bridge program?
No separate enrollment form. Talk to your doctor, they prescribe a Bridge-covered GLP-1, the pharmacy verifies eligibility using your Medicare ID, your doctor submits the coverage approval form, and Medicare mails you a confirmation letter. Then pick up your first month's supply for $50.
Does the $50 count toward my Part D deductible?
No. Bridge payments sit outside your regular Part D benefit and do not count toward your deductible or annual out-of-pocket cap. Bridge drugs are also not eligible for the Medicare Prescription Payment Plan.
What if I have type 2 diabetes or sleep apnea?
You are not eligible for the Bridge. However, your regular Part D plan likely already covers a GLP-1 for those conditions. Contact your plan directly to check coverage for Ozempic, Mounjaro, Wegovy (CV risk reduction), or Zepbound (sleep apnea).
Sources
- Medicare.gov — Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (Official CMS Publication)
- Eli Lilly — What Medicare Part D Patients Need to Know About Accessing Foundayo and Zepbound (July 2026)
- Consultant360 — FDA Approves Oral Semaglutide Pill for Chronic Weight Management (July 30, 2026)
- SHIP — State Health Insurance Assistance Program (Free Medicare Counseling)
Educational content. Not medical advice. Coverage details and eligibility may be updated by CMS during the pilot period. Always verify with your Part D plan and prescriber.